7/27/2019 DIAWPAT

http://slidepdf.com/reader/full/diawpat 1/2

5/7/26AZ- 002380034|AX- 80-J6502C_40|TI- Display for graphical representation of computer data_has OR-gate

inputs connected to comparator and shift register having data inputconnected to other OR-gate|

PA- (GALU/)_GALUZA A S|AU- GALUZA A S|LAZAREVA V P|NP- 001|PN- SU 715567 _A_800125_8040|AN- SU 2339053_760329|AB- An electronic system is designed for the display of graphical

information representing computer data.| The system possesses increasedaccuracy through extension of the data capacity. \|The video-controlunit (1) is forming a raster on the screen on scan synchronisationsignals, and light beam intensity on the video signals.| Agraph-plotter could be used.| With the aid of memory inputs (2, 8) forabsoslute parameters and corrections respectively, the principalcontrolling units, counter (4) and shift register (9) of variablelength, perform the line-by-line scan, synchronising the raster withpulse sequence. \|Comparator (5) and shaper (6) of signal durationcontrol the construction of the horizontal basis.| An important featureis the feed-in of corrective point location by altering the length of

shift register (9).| This device requires 0.4 to 2 bits per point ofthe diagram, where the prototype needs 9.| Hence the capacity is muchincreased.|

DC- T04|DC- R28|IC- G06K-015/20||

6/4/326 (Item 326 from file: 351)FN- DIALOG(R)File 351:DERWENT WPI|CZ- (c) 1994 Derwent Info Ltd. All rts. reserv.|AX- 92-430067_52|AX- <XRAM> C92-191140|

TI- Agent for decreasing cholesterol in blood_comprises triglyceride ofbranched 14-22 carbon fatty acid with alkyl substit. at 2nd position|PA- (NISW )_NISSHIN OIL MILLS LTD|NP- 001|NC- 001|PN- <BASIC> JP 4327559 _A _921117_9252|AN- <PRIORITIES> JP 91122917_910426|AB- <BASIC> JP 04327559_A\|The agent comprises one or more than two

triglyceride(s) having a branched fatty acid whose carbon number in themain chain is 14-22, and which has at least an alkyl substit. at the2nd position.\| Pref., fatty acid is 2-methylpalmitic acid.\|USE/ADVANTAGE - The cholesterol level in blood can be easily decreasedby adding even a small amt. of triglyceride to food.\| In an

example, food contg. 0.8% of 2-methyl palmitic acid triglyceride wasfed to 4 weeks old SD male rat for 2 weeks, and the cholesterol levelin plasma was measured. Total cholesterol was 47.0 (61.2), and the freecholesterol 10.5 (14.1) (control value shown in parenthesis) Dwg.0/0|

FS- CPI|DC- B05|IC- A23L-001/30|A61K-031/23|C07C-069/30|MC- B10-G02|B12-H03||

6/4/304 (Item 304 from file: 351)

7/27/2019 DIAWPAT

http://slidepdf.com/reader/full/diawpat 2/2

FN- DIALOG(R)File 351:DERWENT WPI|CZ- (c) 1994 Derwent Info Ltd. All rts. reserv.|AX- 93-036319_04|AX- <XRAM> C93-016475|TI- New thiazolidinedione derivs._for treating hyperglycaemia and

hypercholesterolaemia by lowering blood glucose and/or cholesterol|PA- (PFIZ )_PFIZER INC|AU- <INVENTORS> GOLDSTEIN S W|HULIN B|NP- 005|NC- 020|PN- <BASIC> WO 9300343 _A1_930107_9304|PN- <EQUIVALENTS> PT 100616 _A _930831_9338|FI 9305823 _A _931223_9410|EP

591252 _A1_940413_9415|JP 6503353 _W _940414_9420|AN- <PRIORITIES> US 720982_910625|AN- JP 92510921_920504|WO 92US3454_920504|WO 92US3454_920504|PT

100616_920623|WO 92US3454_920504|FI 935823_931223|EP 92911176_920504|WO92US3454_920504|

LA- English|CT- EP 299620|EP 428312|DS- <NATIONAL> CA|FI|JP|US|DS- <REGIONAL> AT|BE|CH|DE|DK|ES|FR|GB|GR|IT|LU|MC|NL|SE|LI|FD- JP06503353_Based on_ WO 9300343|EP0591252_Based on_ WO 9300343|AB- <BASIC> WO 9300343 _A\|Thiazolidinedione derivs. of formula (I) and

their salts are new: R = 1-6C alkyl, 3-7C cycloalkyl or phenyl (opt.

mono- or disubstd. by 1-6C alkyl, 1-3C alkoxy, halo or CF3).\|Prepn. of (I) is by reaction of a cpd. of formula (I) with an OH gp. inposition (a) with a silane in strong organic acid or (b) by redn. byhydrogenation at high pressure or high temp.\| USE - (I) are usefulin the treatment of hyperglycaemia and/or hypercholesterolaemia atdaily doses of 0.1 to 50 mg/kg, pref. 0.1 to 10 mg/kg.\| In anexample, soln. of 5-((2-(5-methyl-2-phenyl-4 -oxazolyl)hydroxymethyl)-5-benzofuranylmethyl)-2,4-thiazolidinedione (0.23g) in CF3COOH (3 ml)was treated with Et3SiH (0.21ml). The mixt. was heated at reflux for 1hr. and then diluted with EtOAc (50 ml), washed (H2O (2 x 30 ml), satd.aq. NaHCO3 (2 x 30 ml), water (30 ml) and brine (30 ml)), dried(Na2SO4) and concd. to give a tacky solid which was recrystallised fromEtOH (8-10ml) and H2O (few drops) to give 100 mg of

5-((2-(5-methyl-2-phenyl-4-oxazolyl)methyl) -5- benzofuranylmethyl)-2,4-thiazolidinedione (Ia) (m.pt. 160-161deg.). (Ia) has an ED50 forhypoglycaemic activity at 0.01 mg/kg. \|\| Dwg.0/0|

FS- CPI|DC- B02|IC- A61K-031/425|C07D-413/00|C07D-417/14|MC- B06-A01|B12-H03|B12-H05||